CD8A and neoplasm: In addition, anti-CD96 therapy is effective in enhancing CD8+ T activity and limiting tumor growth and is more effective when administered in combination with blockade of a number of immune checkpoints, including PD-1, PD-L1, TIGIT, and CTLA-4 [47].